Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol

This study has been completed.
Information provided by (Responsible Party):
Meir Medical Center Identifier:
First received: August 1, 2011
Last updated: December 23, 2013
Last verified: August 2011

The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.

Condition Intervention Phase
Drug: estradiol valerate
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • ovum pickup rate that took place between Sunday to Thursday without a compromise [ Time Frame: a year ] [ Designated as safety issue: No ]
    number of Pickups that took place between Sunday to Thursday (without a compromise in treatment) \ by the entire pickup number

Secondary Outcome Measures:
  • pregnancy rate [ Time Frame: a year ] [ Designated as safety issue: No ]
    comparison of pregnancy rate between the 2 groups. calculated per cycle

Enrollment: 63
Study Start Date: August 2011
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Follicular Estrogen, Antagonist, IVF
Follicular Estrogen in Antagonist IVF protocol
Drug: estradiol valerate
2 mg P.O / day for 1-6 days.
Other Name: estradiol valerate
Active Comparator: long IVF protocol
long IVF protocol
Drug: estradiol valerate
2 mg P.O / day for 1-6 days.
Other Name: estradiol valerate

Detailed Description:

A randomised controlled trial in which study group will be given estrogen derivative before ovarian stimulation in GnRH antagonist protocol and compared to the classical GnRH agonist protocol.Estrogen will be given P.O , "PROGYNOVA' , in a dose of 2 mg /d, starting day 2 of menses and until first Monday to follow. Main outcome measure will be ability to control the ovum pickup day, calculated as a rate of ideal pickups divided by the entire pickup number. All women enrolled will be under 38 years of age, with a clear indication for IVF other than ovulatory dysfunction. women with past 4 treatment failures will be excluded as well as cases in which sperm achieved in surgical methods.


Ages Eligible for Study:   up to 38 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • IVF treatment in the following indications: Male, Mechanical, Unexplained
  • Age<38 years
  • Treatment Cycle number 1-4

Exclusion Criteria:

  • Ovulatory disorder as an indication for IVF
  • Repeated failure in previous IVF treatments (> than 4 cycles)
  • Sperm used for treatment was retrieved by surgical procedure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01419353

Meir Medical Center
Kfar Saba, Israel
Sponsors and Collaborators
Meir Medical Center
Study Chair: Adrian Shulman, MD Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center Identifier: NCT01419353     History of Changes
Other Study ID Numbers: Antagonist_prog
Study First Received: August 1, 2011
Last Updated: December 23, 2013
Health Authority: Israel: Clalit Health Services

Keywords provided by Meir Medical Center:
Infertility, IVF, Estrogen

Additional relevant MeSH terms:
Genital Diseases, Female
Genital Diseases, Male
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Hormone Antagonists
Polyestradiol phosphate
Contraceptive Agents
Contraceptive Agents, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 20, 2014